Sage Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Sage Therapeutics CEO'su Barry Greene, Dec2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 6.24M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.8% maaş ve 87.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.14% ine doğrudan sahiptir ve bu hisseler € 457.38K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.3 yıl ve 9.3 yıldır.

Anahtar bilgiler

Barry Greene

İcra Kurulu Başkanı

US$6.2m

Toplam tazminat

CEO maaş yüzdesi	12.8%
CEO görev süresi	4yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	9.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Barry Greene'un ücretlendirmesi Sage Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$338m
Jun 30 2024	n/a	n/a	-US$446m
Mar 31 2024	n/a	n/a	-US$503m
Dec 31 2023	US$6m	US$799k	-US$541m
Sep 30 2023	n/a	n/a	-US$656m
Jun 30 2023	n/a	n/a	-US$592m
Mar 31 2023	n/a	n/a	-US$558m
Dec 31 2022	US$6m	US$761k	-US$533m
Sep 30 2022	n/a	n/a	-US$510m
Jun 30 2022	n/a	n/a	-US$503m
Mar 31 2022	n/a	n/a	-US$484m
Dec 31 2021	US$59m	US$735k	-US$458m
Sep 30 2021	n/a	n/a	US$642m
Jun 30 2021	n/a	n/a	US$666m
Mar 31 2021	n/a	n/a	US$637m
Dec 31 2020	US$836k	US$53k	US$606m

Tazminat ve Piyasa: Barry 'nin toplam tazminatı ($USD 6.24M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.02M ).

Tazminat ve Kazançlar: Barry şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Barry Greene (61 yo)

4yrs

Görev süresi

US$6,237,491

Tazminat

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Barry Greene	President	4yrs	US$6.24m	0.14% € 457.4k
Christopher Benecchi	Chief Operating Officer	less than a year	US$2.28m	0.0081% € 26.8k
Laura Gault	Chief Medical Officer	2.2yrs	US$1.27m	0.018% € 57.7k
Mike Quirk	Chief Scientific Officer	1.3yrs	Veri yok	Veri yok
Ashley Kaplowitz	Director of Investor Relations	no data	Veri yok	Veri yok
Gregory Shiferman	Senior VP & General Counsel	less than a year	Veri yok	Veri yok
Pamela Herbster	VP & Head of People	less than a year	Veri yok	Veri yok
Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance	no data	Veri yok	Veri yok
Vanessa Procter	Senior Vice President of Corporate Affairs	3.1yrs	Veri yok	Veri yok
Aaron Koenig	Medical Director of Early Clinical Development	no data	Veri yok	Veri yok
Maren Killackey	Senior Analyst of Investor Relation	no data	Veri yok	Veri yok
Jeff Boyle	Investor Contact	no data	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: SG7 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Barry Greene	President	4.2yrs	US$6.24m	0.14% € 457.4k
Michael Cola	Independent Director	10.3yrs	US$440.05k	0% € 0
James Frates	Independent Director	10.6yrs	US$435.05k	0.0046% € 15.3k
David Farb	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Geno Germano	Independent Chair of the Board	8.4yrs	US$417.55k	0% € 0
Michael Rogawski	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
James Audia	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Christine Marx	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
A. Morrow	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stephen Moss	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Scott Runyon	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Donald Stein	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

9.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SG7 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/22 12:08
Gün Sonu Hisse Fiyatı	2024/12/04 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Sage Therapeutics, Inc. 39 Bu analistlerden 18, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Joel Beatty	Baird
Esther Lannie Hong	Berenberg
null null	BMO Capital Markets Equity Research

Sage Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. Announces Executive Changes

Insufficient new directors

Insufficient new directors

Insufficient new directors

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

Recent updates

Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease

Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes

Sage Therapeutics, Inc. Announces Executive Changes

Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024

Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Insufficient new directors

Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.70 loss per share (vs US$2.68 loss in 2Q 2023)

Insufficient new directors

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index

Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study

Insufficient new directors

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023)

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Insufficient new directors

Insufficient new directors

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Second quarter 2023 earnings released: US$2.68 loss per share (vs US$2.13 loss in 2Q 2022)

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Sage Therapeutics, Inc. Provides Business Update

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020)

President recently bought €861k worth of stock

Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020)

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €825k worth of stock

Sage Therapeutics, Inc. and Biogen Inc. Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Investor sentiment improved over the past week

Sage Therapeutics, Inc. to Host Sage Science Spotlight: SAGE-718 In Depth

First quarter 2021 earnings released: US$1.64 loss per share (vs US$2.44 loss in 1Q 2020)

Chief Operating Officer has left the company

Sage Therapeutics, Inc. Announces Continued Positive Zuranolone Data for Both 30 Mg and 50 Mg Doses in Open-Label SHORELINE Study in Patients with MDD

Sage Therapeutics, Inc. Announces Departure of Mike Cloonan as Chief Operating Officer, Effective May 3, 2021

Revenue beats expectations

Full year 2020 earnings released: EPS US$11.66 (vs US$13.38 loss in FY 2019)

Sage Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €72.48

Sage Therapeutics, Inc. Appoints Barry Greene as President

Sage Therapeutics, Inc. Enters into A Collaboration and License Agreement with Biogen Ma Inc. and Biogen International Gmbh